Deltic Timber
Molina Healthcare

This year's Fastest-Growing Companies marks the 19th running of the list.

See our methodology and credits



To qualify, a company-domestic or foreign-must be trading on a major U.S. stock exchange; report data in U.S. dollars; file quarterly reports with the SEC; have a minimum market capitalization of $250 million and a stock price of at least $5 on June 30, 2015; and have been trading continuously since June 30, 2012. Companies must have revenue and net income for the four quarters ended on or before April 30, 2015, of at least $50 million and $10 million, respectively; and have posted an annualized growth in revenue and earnings per share of at least 15% annually over the three years ended on or before April 30, 2015.

Companies that meet these criteria are ranked by revenue growth rate; EPS growth rate; and three-year annualized total return for the period ended June 30, 2015. (To compute the revenue and EPS growth rates, Fortune uses a trailing four quarters log linear least square regression fit.)

The overall rank is based on the sum of the three ranks. Once the 100 companies are identified, they are then re-ranked within the 100, using the three equally weighted variables. If there is a tie, the company with the larger four-quarter revenue receives the higher rank.

Excluded are real estate investment trusts, limited liability companies, limited partnerships, business development companies, closed end investment firms, companies about to be acquired, and companies that lost money in the quarter ended on or before April 30, 2015. In addition, Fortune excludes companies that have announced intentions to restate previously reported financial data, if these errors appear to have a significant impact. Also, Fortune excludes companies that lost money in the quarter ended May 31 or June 30, if the loss represents a deterioration in business conditions. The data are provided by Zacks Investment Research. The data checking process was aided by information provided by S&P Capital IQ, Hoover’s, FactSet Research Systems, and Morningstar Document Research.

—By Scott DeCarlo, Douglas G. Elam, Orlaith Farrell, Vivian Giang, Kathleen Smyth

This year's Fastest-Growing Companies marks the 19th running of the list. In our annual list of public companies with the most stellar three-year profit, revenue, and stock growth, Facebook makes its first appearance.

See our methodology and credits


Sort by:
  1. Rank
  2. Revenues
  3. Profits
  4. Mkt Value
  5. Rev Growth
  6. Total Return
Clear Filters

Filter by

Fastest Growing Stats
Gained in Rank
Dropped in Rank
Clear Filters

Clear Filters

View The Full List


A Biogen researcher in their Boston lab working on Alzheimer drug currently in trials.
Photograph by Bob O'Connor for Fortune

Sales of multiple sclerosis drug Tecfidera helped treat this pharmaceutical firm to a hale 2014 (though recent results missed targets).

Company Information

Location Cambridge, MA
Industry Pharmaceuticals
Sector Health Care
Fortune 500 Rank 298
Fortune 500 Profile
Current Streak 1
Years on List 1
CEO George A. Scangos

Revenue, Net Income

$ millions
Revenue Past Four Quarters 10129
Net Income Past Four Quarters 3277

Growth Rates

EPS 3 yr Annual Growth Rate 35%
Rev 3 yr Annual Growth Rate 26%
Total Return 3 yr Annual Rate 41%
Beat S&P 3 yr Total Return?


EPS Growth Rank 69
Revenue Growth Rank 63
Total Return Rank 53
Fortune's Take On Biogen
  • World Leaders Want to End Alzheimer's by 2025. New Clinical Results Show Glimmers of Hope
    In a clinical trial, researchers were able to reduce existing brain plaques and slow the formation of new ones.
  • Biogen's Stock Is Soaring Because of Its Experimental Alzheimer's Drug — But Some Are Urging Caution
    Shares of biotech giant Biogen and partner Eisai were both up 20% Friday.
  • The Diseases We Aren't Curing—And Why
    Drug makers are flocking to certain treatment types. Why do others get left behind?
  • Alzheimer's Cases Are Expected to Double By 2060 and We're Not Ready for It
    There still aren't any truly effective drugs for Alzheimer's or dementia.
  • Sign In


    Thank you for your interest in licensing Fortune content. Please find information on various licensing contacts below and choose the one that best suits your needs:

    • 1. To license Fortune articles, excerpts, or headlines for republication in various media (including books, eBooks, film, web, newsletters, newspapers, magazines and others), please email
    • 2. To license a Fortune cover, order reprint or e-print copies of an article or cover, or license an accolade, please contact PARS International at
    • 3. To license text only photocopies of Fortunearticles as print or digital handouts in academic settings, or in academic coursepacks, please contact the Copyright Clearance Center at